Keta Pandit, MD
Endocrinology, Diabetes & Metabolism · Austin, TXNPI 1336436534
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.9%), consulting fees and education — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Lilly USA, LLC at 55.5% of the total. Reporting peaked in 2021 at $2,886 and has fallen 88.2% since, to $340 in 2025.
Across 133 payments — averaging $40.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$3K
- Novo Nordisk$447
- Sanofi-aventis U.S. LLC$239
- AbbVie$211
- Amgen$171
- Dexcom, Inc.$146
- plus $1K from 27 others
Across 1 payment — averaging $19,250 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tandem Diabetes Care, Inc.$19K
What the payments were for
- Consulting fees$2,60049%
- Food & beverage$2,71351%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 26 | $2,962 |
| Novo Nordisk | 15 | $447 |
| Sanofi-aventis U.S. LLC | 8 | $239 |
| AbbVie(2 entities) | 9 | $211 |
| Amgen | 9 | $171 |
| Dexcom, Inc. | 7 | $146 |
| Radius Health, Inc. | 5 | $106 |
| Medtronic | 5 | $103 |
| Boehringer Ingelheim | 4 | $98 |
| Abbott | 4 | $83 |
| BETA Bionics, Inc. | 3 | $67 |
| Mannkind Corporation | 4 | $66 |
| Amarin Pharma, Inc. | 3 | $63 |
| Novartis | 3 | $62 |
| Corcept Therapeutics | 3 | $57 |
| Xeris Pharmaceuticals, Inc. | 3 | $47 |
| IBSA Pharma Inc. | 3 | $44 |
| Zealand Pharma US, Inc. | 1 | $36 |
| Ascensia Diabetes Care US Inc. | 1 | $35 |
| Insulet Corporation | 2 | $33 |
| Amneal Pharmaceuticals LLC | 2 | $27 |
| Nevro Corp. | 1 | $27 |
| AstraZeneca(2 entities) | 2 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Bayer | 1 | $22 |
| Halozyme Inc | 1 | $20 |
| Cequr Corporation | 1 | $19 |
| Tandem Diabetes Care, Inc. | 1 | $18 |
| Acella Pharmaceuticals, LLC | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $15 |
| Intuity Medical Inc | 1 | $14 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wegovy$101
How this compares
$5,333 in reported general payments places this provider in the 55th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 144 | $194,781 |
| MounjaroTirzepatide | 106 | $158,212 |
| JardianceEmpagliflozin | 94 | $117,116 |
| FarxigaDapagliflozin Propanediol | 76 | $85,849 |
| TrulicityDulaglutide | 37 | $44,942 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $32,112 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $30,389 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $28,716 |
| JanuviaSitagliptin Phosphate | 20 | $26,079 |
| RybelsusSemaglutide | 12 | $20,218 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 72 | $18,073 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $15,587 |
| SynthroidLevothyroxine Sodium | 114 | $7,776 |
| Novolog FlexpenInsulin Aspart | 24 | $7,750 |
| Humalog Kwikpen U-100Insulin Lispro | 20 | $6,605 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $447 | $214,999156 claims |
| Lilly USA, LLCMounjaro, Trulicity | $2,962 | $203,155143 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $98 | $132,703106 claims |
| AstraZenecaFarxiga | $26 | $85,84976 claims |
| AbbVieSynthroid, Armour Thyroid | $211 | $9,045126 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $27 | $4,547326 claims |
| IBSA Pharma Inc.Tirosint | $44 | $3,97111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Austin
- Thomas BlevinsAustin$904K
- Lindsay HarrisonAustin$103K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
- Steve FordanDallas$1.2M
- Rosemarie LajaraPlano$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.